zoonot
virus
circul
swarm
anim
reservoir
emerg
human
popul
caus
epidem
advers
affect
public
health
portabl
safe
effect
vaccin
platform
need
context
outbreak
emerg
situat
work
report
gener
character
alphaviru
replicon
vaccin
platform
base
nonselect
agent
attenu
venezuelan
equin
enceph
vee
viru
vaccin
strain
vrp
use
norovirus
coronavirus
model
system
demonstr
util
vrp
platform
gener
recombin
protein
product
viruslik
particl
vivo
efficaci
vaccin
emerg
virus
importantli
packag
biosafeti
level
condit
distinguish
vrp
previous
report
alphaviru
platform
make
approach
access
major
laboratori
around
world
addit
improv
outcom
vulner
age
model
well
heterolog
challeng
suggest
improv
efficaci
compar
previous
attenu
vrp
approach
take
result
togeth
vrp
platform
repres
safe
highli
portabl
system
rapidli
deploy
condit
gener
candid
vaccin
emerg
microbi
pathogen
import
vee
viru
replicon
particl
provid
robust
establish
platform
antigen
express
vaccin
util
limit
requir
highcontainmentlevel
facil
product
packag
work
util
attenu
vaccin
strain
capabl
use
lower
biocontain
level
retain
capac
wildtyp
replicon
particl
importantli
new
replicon
platform
provid
equal
protect
age
mice
follow
heterolog
challeng
distinguish
attenu
replicon
platform
togeth
new
system
repres
highli
portabl
safe
system
use
context
diseas
emerg
merslik
cov
circul
bat
indic
ongo
threat
human
popul
design
broadli
crossprotect
vaccin
instanc
depend
upon
knowledg
key
antigen
determin
also
avail
rapidrespons
vaccin
platform
easili
gener
character
success
appli
vulner
popul
like
age
alphaviru
replicon
particl
vrp
base
trinidad
strain
venezuelan
equin
enceph
vee
viru
replic
incompet
induc
strong
mucos
cellular
humor
immun
respons
ensur
clinic
safeti
vrp
consist
vee
viru
replicon
rna
encod
replicas
protein
promot
foreign
transgen
express
replicon
rna
lack
structur
gene
helper
rna
provid
tran
produc
infecti
particl
infect
wide
varieti
target
cell
line
host
speci
allow
vaccin
heterolog
express
protein
absenc
preexist
immun
vee
viru
human
popul
also
provid
ad
util
vaccin
platform
use
gener
popul
vrp
base
wildtyp
vee
viru
well
attenu
vee
viru
structur
protein
coat
induc
robust
immun
varieti
antigen
proven
success
vaccin
platform
howev
concern
hamper
vee
viru
vaccin
applic
potenti
replicationcompet
wildtyp
vee
viru
infecti
particl
produc
recombin
copackag
helper
replicon
rna
vee
viru
vrp
retain
risk
wildtyp
vee
viru
infect
diseas
increas
safeti
vrp
vaccin
human
use
preclin
clinic
trial
often
employ
attenu
vee
viru
coat
vee
viru
coat
protein
differ
wild
type
three
amino
acid
attenu
vee
viru
vivo
possibl
enhanc
bind
heparin
sulfat
therebi
lead
acceler
clearanc
viru
blood
vrp
base
coat
shown
success
induc
immun
respons
demonstr
protect
smalland
largeanim
model
viral
diseas
furthermor
attenu
platform
provid
eas
purif
manufactur
process
despit
attenu
vrp
platform
still
retain
risk
vee
virusmedi
diseas
must
packag
safeti
test
biosafeti
level
condit
sarscov
merscov
season
pandem
strain
influenza
viru
pathogen
caus
disproportion
diseas
outcom
elderli
mortal
rate
found
sarscovand
merscovinfect
age
individu
thu
vaccin
age
individu
imper
reduc
overal
morbid
mortal
pathogen
previou
studi
laboratori
demonstr
vrp
provid
partial
protect
heterolog
viru
challeng
young
anim
howev
fail
protect
age
anim
lethal
homolog
heterolog
viru
challeng
use
sarscov
influenza
viru
model
incomplet
protect
failur
protect
immunosenesc
anim
directli
correl
inabl
induc
protect
antibodi
respons
vivo
parallel
studi
vrp
vaccin
also
provid
incomplet
protect
significantli
reduc
lethal
diseas
seriou
clinic
diseas
age
anim
thu
attenu
vrp
produc
platform
less
effect
age
anim
therefor
less
attract
use
human
given
expand
age
popul
next
decad
order
improv
replicon
vaccin
platform
gener
new
vrp
system
util
vee
viru
backbon
vee
viru
live
attenu
vaccin
strain
highli
immunogen
primat
hors
safe
administ
intraperiton
infect
vee
viru
contain
cleavag
site
delet
secondsit
resuscit
mutat
leav
wildtyp
capsid
sequenc
intact
mutat
associ
attenu
phenotyp
observ
strain
work
describ
gener
character
vrp
platform
base
vee
viru
vaccin
strain
confirm
vrp
express
transgen
abil
produc
viruslik
particl
norovirus
addit
test
vrp
express
sarscov
spike
glycoprotein
find
similar
antigen
express
spike
express
vrp
system
similarli
vrp
sar
spike
protect
young
age
mice
lethal
diseas
correl
weight
loss
reduc
viral
replic
gener
neutral
antibodi
homolog
heterolog
strain
importantli
vrp
spike
equival
vrp
spike
superior
vrp
spike
protect
age
mice
lethal
acut
respiratori
diseas
outcom
taken
togeth
data
demonstr
highli
portabl
safe
vrp
platform
confer
robust
expressionvaccin
system
induc
robust
immun
respons
protect
young
age
anim
model
lethal
challeng
construct
character
vrp
vector
platform
alphaviru
replicon
particl
base
wildtyp
vrp
attenu
vrp
surfac
coat
highli
success
vaccin
platform
myriad
concern
limit
use
includ
select
contain
revers
inefficaci
vaccin
platform
vulner
popul
overcom
issu
develop
platform
util
vee
viru
vaccin
backbon
combin
delet
entir
furin
cleavag
site
secondari
site
resuscit
mutat
attenu
viru
packag
fuse
protein
use
human
vaccin
candid
pathogen
base
attenu
vee
viru
strain
gener
new
vrp
vector
platform
fig
system
use
sequenc
wildtyp
vee
viru
includ
untransl
region
utr
structur
glycoprotein
gp
vrp
delet
furin
cleavag
site
attenu
pathogenesi
cell
cultur
mice
second
mutat
glycoprotein
restor
effici
growth
bhk
cell
prevent
revers
virul
secondari
mutat
glycoprotein
gene
well
viral
capsid
gene
insert
separ
helper
construct
subgenom
promot
begin
utr
three
plasmid
linear
rna
transcript
electropor
bhk
cell
h
cell
cultur
supernat
collect
vrp
purifi
titer
determin
bhk
cell
describ
consist
mild
packag
defect
vrp
titer
rang
iuml
log
less
effici
vrp
vrp
coat
fig
importantli
evid
viabl
recombin
electropor
observ
vrp
system
date
replicon
gener
neg
cytopath
effect
cpe
passag
data
shown
examin
possibl
replic
viru
two
stock
vrp
replicon
express
green
fluoresc
protein
gfp
use
infect
vero
cell
subsequ
passag
examin
cpe
gfp
express
fig
follow
initi
passag
vero
cell
show
robust
express
gfp
minim
cpe
day
second
passag
gfpposit
cell
cpe
observ
first
day
final
passag
show
evid
gfp
cpe
suggest
viabl
viru
present
independ
passag
togeth
result
argu
recombin
result
viabl
attenu
vee
viru
unlik
next
character
antigen
express
vrp
platform
use
two
model
antigen
sar
cov
spike
glycoprotein
noroviru
nov
capsid
protein
use
vrp
platform
control
compar
express
sarscov
glycoprotein
vrp
isol
isol
follow
vero
cell
infect
two
independ
experi
demonstr
produc
amount
sarscov
glycoprotein
similar
fig
similarli
nov
vlp
deriv
indistinguish
morpholog
form
particl
characterist
cupshap
surfac
fig
b
addit
particl
microstructur
integr
compar
vrp
platform
base
ligand
bind
effect
concentr
ec
gml
vlp
ec
gml
vlp
fig
mous
polyclon
sera
ec
gml
vlp
ec
gml
vlp
fig
taken
togeth
data
indic
vrp
platform
yield
antigen
express
similar
previou
vrp
platform
ad
util
use
lower
biosafeti
level
efficaci
vrp
vaccin
young
mice
next
analyz
vrp
spike
vaccin
perform
young
mice
parallel
vrp
spike
vrp
spike
group
young
mice
vaccin
boost
week
later
iu
vrp
vaccin
control
vrp
ha
vrpha
encod
influenza
hemagglutinin
blood
collect
day
postprim
week
postboost
anim
challeng
lethal
dose
mouseadapt
sarscov
pfu
anim
vaccin
complet
protect
sarscovinduc
diseas
measur
weight
loss
morbid
death
fig
contrast
anim
lost
bodi
weight
day
postinfect
recov
vrphavaccin
anim
lost
bodi
weight
day
postinfect
experienc
sever
symptom
acut
respiratori
distress
syndrom
ard
diseas
fig
b
analysi
viru
titer
day
postinfect
reveal
anim
vaccin
minim
viral
replic
wherea
anim
protect
viral
replic
similar
vrphavaccin
anim
fig
three
vrp
coat
protect
young
adult
mice
endstag
lung
diseas
mice
vaccin
vrpha
reveal
clear
progress
diffus
alveolar
damag
ard
indic
presenc
hyalin
membran
fig
lower
right
yellow
arrow
contrast
mice
minim
airway
diseas
absenc
major
lung
patholog
base
histolog
score
fig
similar
vaccin
modest
decreas
rel
togeth
result
demonstr
platform
produc
protect
similar
wildtyp
follow
homolog
challeng
also
examin
efficaci
protect
young
mice
heterolog
sarscov
challeng
previou
work
shown
modest
efficaci
platform
rel
follow
heterolog
cov
challeng
studi
anim
challeng
sarscov
chimera
encod
spike
protein
heterolog
strain
mouseadapt
strain
previous
shown
caus
weight
loss
young
anim
signific
airway
diseas
anim
immun
protect
weight
loss
fig
wherea
mockvaccin
anim
lost
bodi
weight
analysi
lung
viral
titer
day
postinfect
reveal
viral
replic
reduc
compar
mockvaccin
anim
fig
notabl
histopatholog
score
indic
neither
platform
abrog
earlystag
diseas
symptom
induc
heterolog
challeng
viru
fig
show
improv
rel
previou
studi
infect
unvaccin
mice
pale
comparison
protect
homolog
challeng
fig
platform
exceed
limit
efficaci
heterolog
challeng
repres
improv
safer
approach
vaccin
gener
develop
vrp
vaccin
platform
protect
age
mice
lethal
sarscov
challeng
previous
demonstr
vrp
vrp
vaccin
effect
protect
age
mice
lethal
sarscov
challeng
diseas
next
evalu
perform
vrp
vaccin
platform
protect
age
mice
lethal
sarscov
challeng
group
anim
vaccin
boost
iu
vrp
vaccin
control
vrpha
serum
collect
week
prime
boost
analyz
antibodi
respons
anim
challeng
pfu
mouseadapt
sarscov
protect
age
mice
sever
sarscovinduc
diseas
evidenc
minim
weight
loss
lethal
fig
b
contrast
anim
receiv
lost
greater
bodi
weight
day
postinfect
die
andor
euthan
fig
b
lung
viru
titer
day
postinfect
fig
reveal
viru
replic
anim
similar
anim
significantli
reduc
compar
vrphavaccin
anim
viru
replic
clear
day
postinfect
age
anim
wherea
viral
titer
remain
high
anim
vaccin
vrpha
anim
lung
patholog
show
littl
evid
denud
airway
cell
airway
debri
fig
airway
mark
green
arrow
minim
inflammatori
cell
infiltr
mark
yellow
arrow
contrast
anim
receiv
vrpha
show
sever
airway
inflamm
denud
bronchiol
mark
green
arrow
accumul
apoptot
debri
sever
peribronchovascular
cuf
character
high
number
lymphocyt
neutrophil
macrophag
mark
yellow
arrow
similar
young
mous
data
result
indic
superior
protect
provid
platform
age
mice
rel
protect
young
mice
age
mice
correl
antibodi
respons
next
analyz
serum
young
age
immun
anim
enzymelink
immunosorb
assay
elisa
indic
sarscov
vaccin
elicit
high
igg
respons
glycoprotein
young
anim
regardless
coat
fig
importantli
platform
elicit
serolog
respons
equival
measur
vaccin
slightli
significantli
lower
antibodi
titer
may
contribut
reduc
protect
young
anim
sarscovinduc
diseas
fig
examin
igg
subtyp
vrp
platform
result
mix
igg
associ
respons
associ
respons
fig
contrast
vrp
produc
strong
igg
respons
minim
sspecif
observ
vrp
mixtur
igg
versu
respons
observ
sever
mice
igg
domin
contrast
sever
other
produc
igg
notabl
vaccin
produc
lower
magnitud
higher
igg
yield
examin
age
mice
elicit
high
antibodi
titer
fig
wherea
vrpha
prove
ineffici
elicit
detect
serolog
respons
notabl
vrp
platform
make
igg
respons
skew
product
seen
young
mice
fig
togeth
sera
young
mice
age
mice
indic
augment
specif
igg
product
skew
toward
igg
compar
platform
extend
analysi
examin
neutral
antibodi
respons
vaccin
use
serum
plaqu
reduct
neutral
assay
prnt
sarscov
prnt
analysi
indic
elicit
high
neutral
antibodi
young
mice
prnt
valu
fig
replic
phenotyp
similar
seen
prnt
valu
fig
prnt
titer
found
lower
anim
like
contribut
partial
protect
seen
homolog
heterolog
challeng
addit
still
effici
elicit
neutral
antibodi
age
mice
prnt
titer
fig
similar
observ
anim
prnt
titer
contrast
littl
neutral
respons
anim
vaccin
togeth
result
clearli
indic
neutral
immun
respons
develop
vaccin
vaccin
demonstr
prefer
platform
futur
vaccin
strategi
alphaviru
replicon
particl
base
wildtyp
vrp
attenu
vrp
surfac
coat
highli
success
vaccin
platform
howev
sever
disadvantag
exist
includ
select
agent
restrict
ii
packag
safeti
test
condit
iii
potenti
gener
wildtyp
vee
viru
due
rna
recombin
iv
potenti
gener
replic
compet
virus
v
failur
vrp
vaccin
protect
age
popul
homolog
heterolog
viru
challeng
strategi
circumv
problem
includ
use
multipl
helper
rna
alphaviru
repliconbas
adjuv
rnaand
dnabas
replicon
launch
platform
absenc
structur
protein
manuscript
develop
character
vrp
platform
highli
portabl
safe
vector
platform
express
novel
gene
featur
similar
earlier
vrp
vrp
iter
importantli
vrp
platform
provid
robust
protect
vulner
popul
context
heterolog
challeng
coupl
increas
safeti
aspect
vrp
system
repres
signific
advanc
potenti
deploy
myriad
emerg
microbi
pathogen
gener
lower
biosafeti
level
attenu
vrp
significantli
expand
number
group
capabl
use
platform
select
agent
rule
concern
revers
wildtyp
viru
render
vrp
vrp
system
inaccess
major
research
group
incorpor
mutat
within
backbon
helper
construct
vrp
platform
overcom
safeti
concern
allow
manipul
addit
vrp
platform
modest
attenu
term
titer
rel
control
like
due
incorpor
mutat
glycoprotein
importantli
vrp
platform
abl
produc
high
concentr
nov
sarscov
glycoprotein
sarscov
produc
level
spike
antigen
similar
nov
norwalk
vlp
produc
within
vrp
system
morpholog
antigen
similar
vlp
express
vrp
provid
platform
manufactur
vlp
vaccin
candid
minor
differ
note
ec
polyclon
antibodi
new
platform
improv
invalu
tool
need
studi
genet
determin
antigen
drift
escap
design
success
noroviru
vaccin
togeth
result
suggest
vrp
system
replic
vrp
amplif
platform
microbi
antigen
abil
provid
vivo
protect
lethal
challeng
human
pathogen
appeal
featur
vrp
platform
allow
rapid
preclin
test
vaccin
vivo
studi
young
mice
immun
demonstr
clear
protect
sarscov
challeng
contrast
coat
provid
suboptim
protect
term
weight
loss
viral
replic
damag
lung
young
mice
similarli
vrp
platform
provid
protect
equival
vrp
context
heterolog
challeng
platform
previous
shown
fail
challeng
result
reduc
weight
loss
viral
replic
diseas
mice
vaccin
notabl
protect
correl
gener
hightit
antigenspecif
antibodi
vrp
platform
produc
antibodi
result
similar
although
directli
test
data
suggest
overal
band
tcell
respons
improv
vrp
vaccin
compar
vrp
vaccin
togeth
result
indic
safer
vrp
platform
outperform
vrp
platform
provid
protect
follow
homolog
heterolog
cov
challeng
sinc
emerg
virus
caus
disproportion
diseas
burden
elderli
success
vaccin
age
individu
vrp
repres
key
public
health
intervent
strategi
effici
protect
age
mice
lethal
sarscov
challeng
indistinguish
neutral
antibodi
play
major
role
protect
evidenc
neutral
titer
similar
titer
measur
vaccin
higher
threshold
need
protect
immun
also
evidenc
clearanc
viru
lung
late
time
postinfect
part
could
due
tcellmedi
respons
shown
play
protect
role
consist
previou
studi
vaccin
fail
elicit
protect
age
individu
perform
similar
control
vrpha
importantli
induc
high
antibodi
titer
neutral
age
absent
suggest
diminish
overal
adapt
immun
respons
respons
skew
toward
virusspecif
antibodi
respons
correspond
similar
result
offer
provid
mechan
protect
age
mice
togeth
data
clearli
demonstr
vrp
improv
attenu
vrp
vaccin
platform
age
mice
sinc
emerg
sarscov
begin
centuri
zoonot
diseas
pose
signific
threat
global
public
health
highli
portabl
safe
vaccin
platform
key
rapidli
respond
emerg
threat
studi
describ
signific
advanc
vee
viru
replicon
particl
vrp
system
make
platform
access
attenu
vrp
system
provid
opportun
use
resourc
lower
biosafeti
level
safeti
incorpor
within
system
sacrific
either
antigen
product
protect
sever
vaccin
condit
overal
result
platform
rapidli
appli
new
emerg
diseas
efficaci
vulner
popul
context
heterolog
challeng
ethic
statement
studi
carri
strict
accord
recommend
care
use
anim
offic
laboratori
anim
welfar
olaw
nation
institut
health
institut
anim
care
use
committe
iacuc
univers
north
carolina
chapel
hill
unc
permit
number
approv
anim
studi
protocol
follow
manuscript
anim
anesthet
ketamin
xylazin
per
iacuc
unc
guidelin
infect
euthan
bodi
weight
drop
start
weight
clinic
symptom
warrant
per
iacuc
unc
guidelin
unc
regist
center
diseas
control
prevent
work
select
agent
includ
sarscov
viru
cell
titer
recombin
sarscov
urbani
strain
icsar
genbank
access
mouseadapt
deriv
mouseadapt
deriv
encod
heterolog
glycoprotein
determin
propag
vero
cell
previous
describ
differ
epidem
strain
sarscov
urbani
amino
acid
spike
protein
genbank
access
strain
sarscov
identifi
sporad
human
case
second
wave
sar
epidem
distinct
urbanideriv
epidem
isol
deriv
molecular
clone
replac
urbani
spike
glycoprotein
encod
mouseadapt
mutat
vero
cell
grown
minim
essenti
medium
mem
invitrogen
carlsbad
ca
supplement
fetalclon
ii
hyclon
south
logan
ut
gentamicinkanamycin
unc
tissu
cultur
facil
sarscov
work
perform
class
ii
biolog
safeti
cabinet
certifi
biosafeti
level
laboratori
contain
redund
exhaust
fan
personnel
wore
tyvek
suit
glove
shoe
cover
use
portabl
air
breath
apparatu
papr
describ
previous
anim
work
perform
sealsaf
hepafilt
mous
cage
specifi
manufactur
techniplast
use
iacucapprov
protocol
procedur
packag
product
vrp
express
sarscov
glycoprotein
differ
coat
vrp
express
sarscov
spike
glycoprotein
vee
viru
coat
construct
previous
describ
assembl
ident
condit
packag
vrp
gene
encod
capsid
envelop
protein
synthes
biobas
inc
insert
psmart
vector
lucigen
inc
vrp
construct
express
sarscov
glycoprotein
gener
use
overlap
pcr
fuse
amplicon
contain
gene
frame
amplicon
contain
sequenc
vee
viru
replicon
primer
vee
viru
replicon
primer
use
gener
gene
amplicon
describ
previous
vrpha
util
coat
gener
previous
describ
ligat
dna
digest
apai
paci
insert
plasmid
vrp
packag
use
helper
rna
encod
structur
protein
describ
gener
polyclon
mous
antisera
neutral
assay
western
blot
analysi
fiveweekold
mice
prime
boost
infecti
unit
iu
vrp
follow
vaccin
mous
polyclon
sera
gener
balbc
mice
describ
previous
neutral
assay
use
mous
antisera
involv
sarscov
perform
describ
previous
western
blot
lysat
cell
infect
vrp
vrp
prepar
describ
detail
blot
probe
use
indic
mous
polyclon
sera
ten
femal
balbc
mice
prime
week
month
age
respect
iu
respect
vrp
mock
vaccin
phosphatebuff
salin
pb
control
titer
vrp
determin
vero
cell
use
antisera
replicas
protein
mice
monitor
day
prime
ensur
unexpect
complic
eg
virusinduc
hind
leg
paralysi
enceph
could
aris
result
gener
authent
vee
viru
recombinatori
process
vivo
occur
serum
collect
tail
nick
method
day
prime
anim
boost
iu
vrp
monitor
daili
describ
previous
twentyon
day
postboost
serum
collect
tail
nick
analysi
anim
immun
perform
condit
anim
transfer
allow
acclimat
least
week
laboratori
avoid
stress
prior
viru
challeng
anim
anesthet
ketaminexylazin
mixtur
intranas
infect
pfu
viru
volum
anim
weigh
daili
clinic
symptom
diseas
monitor
regularli
anim
lost
bodi
weight
euthan
accord
iacuc
guidelin
lung
tissu
harvest
day
postinfect
analyz
viral
titer
histopatholog
viral
host
transcript
chang
result
vaccinationchalleng
determin
lung
titer
briefli
portion
lung
weigh
place
ml
dulbecco
pb
dpb
frozen
analyz
lung
homogen
magna
lyzer
roch
clarifi
centrifug
rpm
min
microcentrifug
viru
titer
within
lung
supernat
assess
via
plaqu
assay
vero
cell
describ
previous
viru
patholog
assess
previous
describ
group
patholog
evalu
lung
harvest
day
postinfect
fix
formaldehyd
formalin
day
ensur
viru
inactiv
formalin
replac
use
fresh
formalin
tissu
transfer
process
condit
lung
tissu
embed
paraffin
cut
tissu
section
stain
hematoxylin
eosin
h
e
identifi
immun
infiltr
lung
patholog
h
estain
section
blind
score
clinic
diseas
featur
includ
airway
diseas
vascular
cuf
pneumonia
diffus
alveolar
damag
scale
mild
sever
norwalk
viruslikeparticl
determin
whether
vrp
platform
could
produc
suffici
protein
product
vlpbase
vaccin
norwalk
viru
gene
insert
directli
vee
viru
replicon
vector
product
vrp
previous
describ
vlp
express
vrpinfect
bhk
cell
purifi
veloc
sediment
sucros
follow
simultan
concentr
dialysi
pb
use
centrifug
filter
unit
millipor
eia
mous
antinorwalk
viru
vlp
polyclon
serum
reactiv
norwalk
viru
vlp
determin
enzym
immunoassay
eia
briefli
plate
coat
decreas
concentr
vlp
pb
addit
serum
primari
antibodi
incub
follow
antimous
igghorseradish
peroxidas
hrp
ge
healthcar
color
develop
onestep
ultra
tmb
elisa
hrp
substrat
solut
thermofish
step
follow
wash
tween
antibodi
dilut
dri
milk
tween
percent
maximum
bind
defin
bind
level
optic
densiti
nm
given
vlp
concentr
divid
bind
level
gml
vlp
multipli
data
fit
sigmoid
doserespons
curv
prism
graphpad
ec
calcul
ec
vlp
gener
differ
vrp
coat
compar
use
student
test
differ
consid
signific
p
valu
vlpcarbohydr
ligandbind
assay
pig
gastric
mucin
type
iii
pgm
sigma
chemic
solvat
pb
mgml
coat
onto
eia
plate
gml
pb
h
block
overnight
dri
milk
tween
decreas
concentr
norwalk
viru
vlp
ad
h
bound
vlp
detect
mous
antinorwalk
vlp
monoclon
antibodi
gml
follow
antimous
igghrp
ge
healthcar
color
develop
onestep
ultra
tmb
elisa
hrp
substrat
solut
thermofish
incub
done
room
temperatur
step
follow
wash
tween
reagent
dilut
dri
milk
tween
data
analyz
describ
eia
statist
approach
statist
analysi
perform
use
prism
graphpad
san
diego
ca
softwar
nonparametr
mannwhitney
student
test
perform
gener
p
valu
note
text
research
support
grant
niaid
nia
nih
mth
rsb
rsb
vdm
wellcom
trust
rsb
thank
victoria
madden
microscopi
servic
laboratori
depart
patholog
laboratori
medicin
univers
north
carolinachapel
hill
expert
technic
support
content
sole
respons
author
necessarili
repres
offici
view
nih
